Form 4 for JBIO Jade Biosciences, Inc.
Accepted 2022-10-20 00:00:00 ET · period of report 2022-10-18 · accession 0001415889-22-010741 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-10-20 | 2022-10-18 | JBIO | Dake Benjamin T | SEE REMARKS | S - Sale+OE | $21.08 | -5,705 | 0 | -100% | -$120.3K |
| D | 2022-10-20 | 2022-10-18 | JBIO | Dake Benjamin T | SEE REMARKS | M - OptEx | $2.14 | +5,705 | 5,705 | New | +$12.2K |
| D | 2022-10-20 | 2022-10-18 | JBIO | Dake Benjamin T | SEE REMARKS | M - OptEx | $0.00 | -5,705 | 299.2K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-10-18 | S | D | 5,705 | $21.08 | 0 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.665 to $21.355, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 2 | Common | Common Stock | 2022-10-18 | M | A | 5,705 | $2.14 | 5,705 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-10-18 | M | D | 5,705 | $0.00 | 299,166 | D | $2.14 · — to 2031-04-01 | 5,705 Common Stock | (F3) A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. |